|
|
| (3 intermediate revisions by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Doxazosin#Nonclinical Toxicology]] |
| {{Doxazosin}}
| |
| {{CMG}}; {{AE}} {{AK}}
| |
| | |
| ==DRUG INTERACTIONS==
| |
| | |
| Most (98%) of plasma doxazosin is protein bound. In vitro data in human plasma indicate that doxazosin has no effect on protein binding of [[digoxin]], [[warfarin]], [[phenytoin]], or [[indomethacin]]. There is no information on the effect of other highly plasma protein- bound drugs on doxazosin binding. Doxazosin has been administered without any evidence of an adverse drug interaction to patients receiving [[thiazide ]]diuretics, beta-blocking agents, and nonsteroidal anti-inflammatory drugs. In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of doxazosin on day 1 of a four-day regimen of oral [[cimetidine ]](400 mg twice daily) resulted in a 10% increase in mean AUC of doxazosin (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of doxazosin. The clinical significance of this increase in doxazosin AUC is unknown.
| |
| | |
| In clinical trials, doxazosin tablets have been administered to patients on a variety of concomitant medications; while no formal interaction studies have been conducted, no interactions were observed. Doxazosin tablets have been used with the following drugs or drug classes: 1) analgesic/anti-inflammatory (e.g., [[acetaminophen]], [[aspirin]], [[codeine ]]and [[codeine ]]combinations, [[ibuprofen]], [[indomethacin]]); 2) antibiotics (e.g., [[erythromycin]], [[trimethoprim ]]and [[sulfamethoxazole]], [[amoxicillin]]); 3) antihistamines (e.g., [[chlorpheniramine]]); 4) cardiovascular agents (e.g., [[atenolol]], [[hydrochlorothiazide]], [[propranolol]]); 5) [[corticosteroids]]; 6) gastrointestinal agents (e.g., [[antacids]]); 7) hypoglycemics and endocrine drugs; 8) sedatives and tranquilizers (e.g., [[diazepam]]); 9) cold and flu remedies.
| |
| | |
| Concomitant administration of doxazosin with a [[PDE5 inhibitor|phosphodiesterase-5 ]](PDE-5) inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension (see[[Doxazosin dosage and administration|DOSAGE AND ADMINISTRATION]]).<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = DOXAZOSIN TABLET [APOTEX CORP.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=4fa5c2f7-cda9-56cd-622f-b3d05dc7c94b | publisher = | date = | accessdate = 7 March 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |